By supporting diagnosis and patient management in gastroenterology, SCHEBO kits can optimise patient management, helping save costs and resources.
The ScheBo Tumor M2-PK Stool Test brings high sensitivity to non-invasive bowel cancer screening. Unlike FOB tests, it is not dependent on bleeding from tumours or polyps and just requires a sample from only a single stool. A new independent assay service is now available. Tumor M2-PK levels in EDTA-plasma samples can help diagnose many gastrointestinal tumours and support patient monitoring.
The ScheBo Pancreatic Elastase 1 Stool Test is generally regarded as the noninvasive “test of choice” for measuring pancreatic exocrine function. The results help decide whether prescribing of costly enzyme replacement therapy is appropriate.
